Life Sciences Digital Innovation Hub Cluster
Life Sciences Digital Innovation Hub (LS DIH Lithuania) Cluster is a platform for business-research partnership, dedicated to fostering digital innovation in the life sciences, bringing together research, business and public sector institutions and organizations.
The cluster develops its activities in Vilnius City Innovation Industrial Park, paying special attention to clustering and strengthening cooperation of companies operating in the fields of biochemistry, biotechnology, molecular biology, genetics, neurobiology, molecular medicine, clean technologies, information technologies and related areas. By providing consulting services and ensuring access to competencies and infrastructure located at Vilnius University Life Sciences Center and Vilnius City Innovation Industrial Park, LS DIH Lithuania aims:
- to promote the implementation of new bioinformatics projects in the field of life sciences and health;
- to develop the methods for processing and analyzing big data generated during life science research;
- to enable companies developing new biotechnological and digital products to validate them through clinical research practices;
- to design and develop digital equipment for use in biomedical practice and diagnostics;
- to support the creation of start-ups, small and medium-sized enterprises offering digital solutions for the life sciences industry;
- to improve access to finance for technology transfer and digitization projects;
- to share experiences and good practices in the life sciences industry sector;
- to provide comprehensive assistance in the development of new products.
Coordinator of Life Sciences Digital Innovation Hub Cluster – Northtown Vilnius – has accumulated significant experience in developing entrepreneurship, promoting cooperation between science and business, and providing innovation support services over the last two decades. Currently, Northtown Vilnius focuses its activities on two directions: developing innovative R&D investment zones and individual objects of the innovation system, and providing high value services through science and business cooperation, R&D and innovation.
Baltic Institute of Advanced Technology
Baltic Institute of Advanced Technology (BPTI) is a private, high tech oriented research institute. BPTI focuses on creating and developing new technologies and providing R&D services to other companies. Their strength comes from the ability to gather interdisciplinary research teams which can provide efficient solutions to difficult problems.
“Bioanalizes sistemos” a company that manufactures a multifunctional biosensor for hemodialysis patients, also develops innovative devices capable of performing tests of various substances (blood, industrial fluids) in any environment ten times faster than using conventional technologies.
“Biomatter Designs” is pioneering the technology for Protein Design for the next-generation manufacturing and therapeutic applications. The AI-based generative approach enables the effective construction of new proteins with the desired functions right from the first atom.
“CasZyme” is a startup company which aims to develop new discoveries, innovative applications and top-quality research in the field of CRISPR based Molecular Tools. The company seeks to create outstanding value for researchers and companies practicing gene-editing worldwide.
Cumulatis develops bioengineering solutions for bioreactor systems from flask experiments in laboratories to industrial installations. The solutions created in the company are validated by cultivating cultures of microorganisms (recombinant E.Coli, mammalian, and stem cells) and ending with verification in macroorganisms, searching for potential applications in medicine. The company also participates in development services and technology transfer activities with partners in Lithuania and abroad.
“Diagnolita” is a start-up company devoted to the introduction of innovative molecular diagnostics tests into medical practice. The company is focused on the development of non-invasive means for prostate cancer diagnostics. The professional and experienced team exploits several modern technologies in research and development and works in a creative environment.
“Droplet Genomics” makes microfluidic instruments, consumables and data analysis tools – so biological samples can be analyzed at the granularity of single cells. This generates enough data to reveal biological mechanisms and makes it possible to predict the future, rather than characterize the present.
“Experimentica” offers scientific know-how and expertise in preclinical ocular drug development. Their world-class scientists use multiple experimental platforms, from cell culture to complex in vivo models, to deliver the highest quality science. With R&D laboratories in USA, Lithuania and Finland, and local representation in France and China, “Experimentica” serves pharma, biotech and academic customers globally.
“Grida” activity – supply and design of high quality laboratory reagents, accessories, equipment and furniture, service and maintenance. Since 1992, it has been one of the leading suppliers in this field in Lithuania, representing such manufacturers as Eppendorf, Tecan, Cytiva, Carl ROTH and others. The company’s specialists advise clients from laboratory planning to method development.
“Inlita” focuses on helping broaden and develop biomedical sciences in Lithuania by introducing sponsors to better investment opportunities. The company’s vision is to create a ‘one stage’ procedure so that any sponsor would be able to implement a clinical trial project across Lithuania. “Inlita” is operating in 4 clinical trials sites.
Institute of Infectious Diseases and Pathogenic Microbiology
The Institute of Infectious Diseases and Pathogenic Microbiology (IIDPM) specializes in complex multistage preclinical studies of the efficacy of new antimicrobial drugs, the development of drug pharmacodynamics kinetics, and the evaluation of tissue effects in in vitro and in vivo systems. In cooperation with Lithuanian, European and US scientific and medical institutions, the IIDPM team pays special attention to the research of multidrug-resistant microorganisms and the development and research of new antiviral drugs
“Sanobiotec” is a research company committed to identification, development and formulation of innovative active compounds. The company operates a state-of-the-art laboratory and develops proprietary technological solutions designed for production of natural and custom compounds. “Sanobiotec” is also engaged in scientific research projects investigating the potential of cannabinoid-based medications used for treatment of specific diseases.
Three Thirds helps companies increase their products value through artificial intelligence technologies. The team of scientists and engineers delineate AI strategies, build data infrastructure and algorithms, and deliver production-level machine learning solutions to process automation and optimization.
Vilnius City Municipality
The City of Vilnius has been operating most effectively in Lithuania for the third year in a row. City council’s priorities include: to create and implement a strategic vision of a city, to attract investments, and to operate transparently, quickly and be open to residents, guests and investors.
Vilnius University Life Sciences Center
VU Life Sciences Center (VU LSC) is a leader in the life sciences in Lithuania not only in terms of infrastructure, but also in terms of ideas. The achievements of their researchers and students are highly valued in the world, and internationality as well as innovativeness are essential features of LSC. VU LSC is open to the public – representatives of other scientific institutions and the country’s businesses are invited to use the unique equipment, available at the LSC Open Access Center.